Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple‐negative breast cancer

Abstract

Key Clinical MessageIn a patient with metastatic breast cancer, an acquired BRCA mutation in the BRCA gene was detected, resulting in benefits from olaparib treatment. This underscores the importance of ongoing genetic phenotype testing after paclitaxel chemotherapy.AbstractTriple‐negative breast cancer (TNBC) is associated with a poor prognosis and elevated mortality risk. BRCA mutations are commonly regarded as prevalent mutations in TNBC patients, strongly associated with congenital familial heredity. Dynamic changes in mutation sites, however, are rarely reported. In this case report, we report a 59‐year‐old TNBC patient who developed pulmonary metastases post‐chemoradiotherapy. No BRCA mutations were detected through NGS. After 7.6 months of nab‐paclitaxel treatment, the patient experienced progression of lung metastases, and BRCA mutations were detected through NGS testing. Subsequent administration of olaparib resulted in a reduction in lung metastasis, demonstrating significant therapeutic efficacy. This case underscores the infrequent occurrence of treatment‐induced BRCA mutations and emphasizes the significance of dynamic NGS genetic testing for real‐time assessment of a patient's mutational status.